title: Mode of delivery in pregnant women with hypertensive disorders and unfavorable cervix following induction of labor with vaginal application of prostaglandin E.
abstract: BACKGROUND
  Our aim was to evaluate the mode of delivery in pregnant women with hypertensive disorders and unfavorable cervix following induction of labor with vaginal application of prostaglandin E(2) (PGE(2)) near or at term, and to define the predictors of successful vaginal delivery in such women.
  
  
  METHODS
  In a retrospective case-controlled study, pregnant women with hypertension, who underwent labor induction with PGE(2) tablets (study group, n = 284), were compared with women, who underwent elective induction of labor (group 2, n = 115), and women with normal spontaneous onset of labor (group 3, n = 510).
  
  
  RESULTS
  The rate of cesarean section (CS) was significantly higher in the study group (25.3%) than in group 2 (14.8%) and in group 3 (9%). Exclusion of the nulliparous women from the study and control groups yielded similar CS rates in the study group (16.9%) and in group 2 (11.1%). Women with pre-eclampsia and the women with chronic hypertension or pregnancy-induced hypertension had similar rates of CS. In logistic regression model, nulliparity, induction of labor with PGE(2), and maternal age, but not hypertensive disorders, were independently and significantly associated with increased risk of CS.
  
  
  CONCLUSIONS
  PGE(2) induction of labor is successful in approximately 75% of patients with hypertensive disorders and unfavorable cervix, with apparently no serious maternal or fetal complications. The induction of labor by itself, and not the hypertensive disorders in pregnancy, is independent risk factor for CS.
authors.affiliation: Perinatal Division and WHO Collaborating Center for Perinatal Care, Department of Obstetrics and Gynecology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel. yudavi@inter.net.il
authors.forename: Avi
authors.initials: A
authors.lastname: Ben-Haroush
authors.forename: Yariv
authors.initials: Y
authors.lastname: Yogev
authors.forename: Hagit
authors.initials: H
authors.lastname: Glickman
authors.forename: Boris
authors.initials: B
authors.lastname: Kaplan
authors.forename: Moshe
authors.initials: M
authors.lastname: Hod
authors.forename: Jacob
authors.initials: J
authors.lastname: Bar
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D000704:Analysis of Variance; D020070:Cervical Ripening; D036861:Delivery, Obstetric / Q000379:methods*; D015237:Dinoprost / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005865:Gestational Age; D006801:Humans; D046110:Hypertension, Pregnancy-Induced; D007751:Labor, Induced; D016015:Logistic Models; D010120:Oxytocics / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome
chemical_list: D010120:Oxytocics; D015237:Dinoprost